‹ ফিরে যান

Liquid Biopsy: Can Cancer Be Detected Through a Simple Blood Test?

Liquid Biopsy, Cancer Detection, Cancer Genomic Testing, ctDNA Testing, Cancer Treatment in India, Medical Tourism in India

Welltara Team LogoWelltara Team
Blog Date October 26, 2026
Blog Time 6 Min Read
Liquid Biopsy: Can Cancer Be Detected Through a Simple Blood Test?

When people think about a cancer biopsy, they often imagine a procedure involving a needle or surgery, followed by a period of waiting for the results. So, when they hear that a blood sample may reveal important information about cancer, a natural question follows: can cancer really be detected through a simple blood test?

The answer is yes, in certain situations. This technology is known as liquid biopsy, and it is becoming an important tool in selected areas of cancer care. It can help doctors identify certain genetic changes in a tumour, evaluate potential treatment options and investigate how a cancer may be changing over time.

However, liquid biopsy is not a universal cancer detection test. It cannot reliably detect every cancer, and it does not replace conventional tissue biopsy or established cancer screening methods in all situations.

In this guide, we explain what liquid biopsy is, how it works, where it is used, its limitations and what patients should discuss with their oncologist. We also cover what international patients should know when exploring cancer treatment in India.

Welltara is a healthcare facilitation service that helps patients explore hospital and specialist options and coordinate practical arrangements for care. This article is intended for general education and is not a substitute for professional medical advice.

What Is a Liquid Biopsy?

A liquid biopsy is a laboratory test that analyses a body fluid, most commonly blood, to look for biological information associated with cancer.

Depending on the test, the sample may be analysed for:

  • Circulating tumour DNA (ctDNA): Small fragments of DNA released by tumour cells into the bloodstream.
  • Circulating tumour cells (CTCs): Cancer cells that have entered the bloodstream.
  • Other cancer-associated biomarkers: Certain tests investigate additional biological signals that may provide information about a tumour.

Unlike a conventional tissue biopsy, which involves collecting a sample of tissue for examination, a liquid biopsy uses a fluid sample. This can make repeated testing more convenient in appropriate clinical situations.

One established use of liquid biopsy is to identify certain tumour-related genetic alterations in patients who have already been diagnosed with cancer. These results may help oncologists evaluate treatment options or obtain additional information when a tissue sample is unavailable or insufficient.

The usefulness of the test depends on the cancer type, the specific test and the clinical question the doctor wants to answer.

How Does Liquid Biopsy Work?

Liquid biopsy works by detecting and analysing biological material associated with a tumour. One important target is circulating tumour DNA, commonly known as ctDNA.

Cells naturally release DNA fragments into the bloodstream. Tumour cells can also release DNA carrying genetic changes associated with cancer. A laboratory can analyse a blood sample using specialised molecular testing methods to look for particular alterations.

For example, if a patient has a type of lung cancer associated with a genetic alteration that may influence treatment selection, an appropriately validated liquid biopsy test may help identify that alteration.

However, detecting ctDNA is not always straightforward. Small or early-stage tumours may release very little tumour-related DNA into the bloodstream. The amount detected can also vary according to the cancer type, tumour location and other biological factors.

This is one reason why liquid biopsy tests differ in their performance and why results must be interpreted in the context of the patient's medical history, other investigations and the test's validated purpose.

Liquid Biopsy vs Tissue Biopsy: What Is the Difference?

Liquid biopsy and tissue biopsy provide different types of information. Neither method is automatically the best option for every patient.

Tissue Biopsy

A tissue biopsy involves collecting a sample from a suspected tumour. A pathologist examines the sample to help establish the diagnosis and identify the type of cancer. Additional laboratory tests may provide information about the tumour's characteristics and potential treatment options.

Tissue biopsy remains essential for diagnosing many cancers.

Liquid Biopsy

A liquid biopsy usually involves collecting a blood sample and analysing it for specific tumour-related genetic changes or other biomarkers.

It may help identify actionable genetic alterations, particularly in selected patients with advanced cancer. It may also be useful when obtaining tumour tissue is difficult or when a tissue sample does not provide enough material for the required molecular testing.

Can Liquid Biopsy Replace Tissue Biopsy?

In most situations, liquid biopsy should not be considered a complete replacement for tissue biopsy. A blood-based test may not provide enough information to establish the exact cancer diagnosis and can miss genetic alterations present in the tumour.

If a liquid biopsy result is negative or inconclusive, the oncologist may recommend tissue-based testing or another investigation, depending on the clinical situation.

The two methods can complement each other. The appropriate approach depends on the patient's diagnosis, the availability of tissue and the information needed to guide care.

Can Liquid Biopsy Detect Cancer Before Symptoms Appear?

One of the most common questions about liquid biopsy is whether a blood test can detect cancer before a person develops symptoms.

Researchers are investigating blood-based tests that look for biological signals associated with multiple cancer types. Some specific blood tests are authorised for defined screening purposes, but this does not mean that a single test can reliably detect every cancer in an otherwise healthy person.

For example, in July 2024, the US Food and Drug Administration (FDA) approved the Shield blood test for colorectal cancer screening in adults aged 45 and older who are at average risk. This approval applies to a specific test and a defined screening purpose. It does not establish the test as a universal cancer screening method. A negative result also does not guarantee that colorectal cancer is absent.

Multi-cancer early detection tests are an active area of research. Their performance, appropriate use and impact on patient outcomes continue to be investigated.

There are several important limitations to understand:

  • Early cancers may be missed: Small tumours may release too little detectable material into the bloodstream.
  • False-positive results can occur: A test may indicate a possible abnormality that requires further investigation but does not ultimately confirm cancer.
  • Further testing may be necessary: A positive or inconclusive result may require imaging, colonoscopy, tissue biopsy or other investigations, depending on the test.
  • A negative result is not a guarantee: The meaning of a negative result depends on the test and the clinical context.

Liquid biopsy should not be assumed to replace recommended screening tests such as mammography, cervical cancer screening, colorectal cancer screening or low-dose CT screening for eligible individuals.

If you have symptoms or concerns about cancer, consult a qualified healthcare professional rather than relying on a blood test alone.

What Is Liquid Biopsy Used for in Cancer Care?

Liquid biopsy has several potential and established applications, although the evidence and clinical usefulness vary by test and cancer type.

1. Identifying Genetic Changes That May Guide Treatment

Some cancers have specific genetic alterations that can influence the choice of targeted therapies. In selected patients, a validated liquid biopsy test may help identify these alterations.

The results can help an oncologist evaluate whether a particular treatment may be appropriate. Not every genetic alteration has an available targeted treatment, and the final decision depends on the patient's complete clinical assessment.

2. Supporting Molecular Testing When Tissue Is Unavailable

Sometimes, collecting a tumour tissue sample is difficult, unsafe or not possible. In other cases, the available sample may not contain enough material for all the required tests.

In selected situations, liquid biopsy may provide useful additional genetic information. However, a negative or non-informative result does not necessarily mean that the tumour lacks the genetic alteration being investigated.

The oncologist may recommend tissue testing or another method if further information is needed.

3. Investigating Changes During Treatment

Some liquid biopsy tests can identify changes in tumour-related DNA over time. Depending on the cancer and the test, this information may help doctors investigate the tumour's molecular characteristics during treatment.

However, changes in ctDNA levels should not automatically be interpreted as proof that treatment is working or failing. Results need to be assessed alongside clinical findings, imaging and other investigations.

4. Investigating Potential Treatment Resistance

Cancer cells can acquire genetic changes that affect how they respond to particular medicines. In selected cases, repeat molecular testing may help identify alterations associated with resistance to a treatment.

This information may support further clinical evaluation, but a test result alone does not determine the next treatment.

5. Studying Minimal Residual Disease

Minimal residual disease refers to small amounts of cancer that may remain after treatment, even when routine investigations do not show clear evidence of disease.

Certain tests can investigate tumour-related DNA after treatment to look for molecular signs associated with residual disease or a possible future recurrence.

However, the clinical usefulness of these tests varies by cancer type and setting. Detecting a molecular signal does not automatically mean that changing treatment based on the result will improve outcomes. Such testing should be discussed with the treating oncologist.

6. Supporting Cancer Research

Liquid biopsy is also being studied in clinical trials and other research settings. Researchers are investigating whether it can improve early detection, treatment selection and monitoring in different cancer types.

The fact that a test is being researched does not necessarily mean that it is suitable for routine clinical use.

What Are the Limitations of Liquid Biopsy?

Understanding the limitations of liquid biopsy is just as important as understanding its potential benefits.

It Cannot Detect Every Cancer

Different tumours release different amounts of DNA and other biological material into the bloodstream. Some cancers may be difficult to detect using a particular blood-based test. A negative result should be interpreted according to the test's intended use and the patient's clinical circumstances.

It Does Not Replace Every Tissue Biopsy

A liquid biopsy may provide genetic information, but it generally cannot provide the same tissue structure and microscopic detail as a conventional biopsy. Tissue testing may still be necessary to confirm the diagnosis, classify the cancer or investigate alterations that a blood-based test may not detect reliably.

Results Require Specialist Interpretation

Not every genetic alteration detected in blood necessarily comes from a tumour. Some changes can originate from normal blood cells or other biological processes. A qualified specialist must interpret the result in the context of the patient's medical history, other test results and the laboratory's findings.

Test Performance Varies

Different tests are designed for different purposes. A test validated for identifying certain genetic alterations in an established cancer should not automatically be assumed to work for early cancer screening or treatment monitoring.

Patients should ask whether the particular test has been validated for their cancer type and the clinical question being investigated.

Cost and Availability May Vary

The cost, availability and reporting time for liquid biopsy depend on the test, laboratory and healthcare provider. Before proceeding, patients should confirm the total cost, the expected turnaround time and whether the test result is likely to influence a clinical decision.

Is Liquid Biopsy Testing Available in India?

Liquid biopsy and blood-based molecular testing may be available through selected cancer centres and diagnostic laboratories in India. However, the tests offered and their clinical applications vary between providers.

Some tests are used to investigate tumour-related genetic alterations in patients who have already been diagnosed with cancer. Other applications may be available only in specific clinical settings or research programmes.

Patients considering testing in India should confirm the following with their treating doctor and the proposed laboratory:

  • Is the test appropriate for the patient's cancer type and stage?
  • What specific genetic alterations or biomarkers does it analyse?
  • Is the test validated for the intended clinical purpose?
  • Does the laboratory have the relevant accreditation and quality assurance processes?
  • How will the results influence the treatment discussion?
  • Will additional tissue testing or imaging be needed?
  • What is the total cost, and when can the report be expected?

International patients should also check whether the selected hospital has the relevant oncology specialists and diagnostic services available for their specific needs.

Explore all treatments listed by Welltara or learn more about cancer treatment in India for international patients.

The availability of a particular test should be confirmed directly rather than assumed based on a hospital's general cancer care services.

Who Might Be Advised to Consider a Liquid Biopsy?

Whether liquid biopsy is appropriate depends on the patient's diagnosis and the clinical question that needs to be answered. An oncologist may consider discussing it in situations such as:

  • A patient with an established cancer diagnosis who needs testing for specific tumour-related genetic alterations.
  • A patient with advanced cancer whose doctor is evaluating targeted treatment options.
  • A situation in which obtaining tumour tissue is difficult or the available sample is insufficient for molecular testing.
  • A selected case in which repeat molecular testing may provide information about changes associated with treatment resistance.
  • A clinical setting in which a validated blood-based test is appropriate for a defined monitoring purpose.

These examples do not mean that every patient with cancer needs a liquid biopsy.

For people without symptoms or a cancer diagnosis, a liquid biopsy should not be assumed to be a standard screening recommendation. The appropriate screening plan depends on factors such as age, medical history, family history and recognised risk factors.

Always discuss the benefits, limitations and alternatives with a qualified healthcare professional before choosing a test.

What Questions Should You Ask Your Oncologist Before a Liquid Biopsy?

A consultation is an opportunity to understand whether a test is likely to provide useful information. Consider asking your oncologist the following questions:

  1. Is liquid biopsy appropriate for my cancer type and stage?
  2. What specific information is this test intended to provide?
  3. Could the result change the treatment options being considered?
  4. What would a negative or inconclusive result mean in my situation?
  5. Will I still need a tissue biopsy or other investigations?
  6. Is the test validated for the purpose for which it is being recommended?
  7. How much will the test cost, and how long will the results take?
  8. Who will explain the report and discuss the next steps with me?

These questions can help you understand the role of the test and make a more informed decision with your treating doctor.

Common Myths About Liquid Biopsy

Myth 1: One Blood Test Can Detect Every Type of Cancer

Fact: No single liquid biopsy test can reliably detect every cancer in every person. Performance depends on the test, the cancer type, the disease stage and the amount of detectable biological material in the sample.

Myth 2: A Negative Result Means There Is No Cancer

Fact: A negative result does not rule out every cancer. Some tumours release very little detectable material, and a test may miss alterations that are present in the tumour.

Myth 3: Liquid Biopsy Means Tissue Biopsy Is No Longer Necessary

Fact: Tissue biopsy remains important for diagnosing many cancers. Liquid biopsy can provide additional information in selected situations, but it does not replace all tissue-based investigations.

Myth 4: Liquid Biopsy Is Always Better Because It Is Less Invasive

Fact: A blood sample is generally easier to collect than a tissue sample, but convenience does not mean that the test is more informative or suitable for every clinical question.

Myth 5: Every Liquid Biopsy Test Can Monitor Treatment or Predict Recurrence

Fact: Different tests have different validated uses. The clinical value of treatment monitoring and recurrence-related testing varies, and the results must be interpreted by the treating medical team.

How Welltara Can Help International Patients Explore Cancer Care in India

Understanding cancer investigations and comparing hospital options can be challenging, particularly when care is being considered in another city or country.

Welltara is a healthcare facilitation service that helps international patients organise their medical records, explore suitable hospital and specialist options, coordinate appointments and understand practical arrangements related to treatment travel.

If your treating doctor has recommended liquid biopsy, cancer genomic testing or an oncology second opinion, Welltara can help you explore relevant hospital options, subject to the availability of services and the hospital's clinical assessment.

Depending on the patient's requirements, exploring specific cancer care services may also be relevant:

These pages provide information about different cancer care options. The appropriate specialist, investigation and treatment depend on the patient's individual clinical assessment.

Our role is to support the coordination process. Welltara does not diagnose cancer, prescribe medicines or make treatment decisions. The treating medical team remains responsible for evaluating the patient's condition, recommending appropriate investigations and discussing treatment options.

Exploring Cancer Care in India?

If you or a family member is considering cancer care in India, Welltara can help you explore relevant hospital and specialist options and understand the practical steps involved in arranging a consultation.

Contact Welltara to discuss your requirements.

The Bottom Line: Can Cancer Be Detected Through a Blood Test?

Liquid biopsy is an important development in cancer diagnostics and molecular testing. In selected situations, it can provide useful information about tumour-related genetic changes and help oncologists evaluate treatment options.

However, it is not a universal cancer detection test. It cannot reliably identify every cancer, and it does not replace tissue biopsy or established screening methods in all circumstances.

The most appropriate use of liquid biopsy depends on the cancer type, the patient's clinical situation, the specific test and the decision the medical team needs to make.

If a doctor has recommended this investigation, ask what information the test is expected to provide, what its limitations are and whether additional tests may be required.

For international patients exploring cancer care in India, Welltara can assist with hospital and specialist coordination while medical decisions remain with the qualified treating team.

Frequently Asked Questions About Liquid Biopsy

What Is a Liquid Biopsy in Simple Terms?

A liquid biopsy is a laboratory test, usually performed on a blood sample, that looks for tumour-related DNA, circulating tumour cells or other cancer-associated biomarkers. Its purpose depends on the specific test being used.

Can a Liquid Biopsy Diagnose Cancer on Its Own?

A liquid biopsy does not replace the full diagnostic process for most cancers. Doctors may need tissue biopsy, imaging and other investigations to confirm a diagnosis and determine the cancer type.

Is a Liquid Biopsy Painful?

A blood-based liquid biopsy generally involves a routine blood draw. The experience is similar to having blood collected for other laboratory tests.

Can Liquid Biopsy Detect Every Type of Cancer?

No. The ability to detect cancer depends on the type of test, the cancer involved, the disease stage and the amount of detectable tumour-related material in the blood.

Can a Liquid Biopsy Detect Cancer Before Symptoms Appear?

Some specific blood-based tests are authorised for defined screening purposes, while other early-detection applications are still being studied. Liquid biopsy should not be treated as a universal cancer screening test.

Can Liquid Biopsy Replace a Tissue Biopsy?

Usually not. Tissue biopsy remains important for diagnosing and classifying many cancers. Liquid biopsy may provide additional molecular information in selected situations.

How Long Does a Liquid Biopsy Take to Provide Results?

The turnaround time depends on the test, laboratory and type of analysis. Ask the laboratory or treating hospital for the expected reporting time before proceeding.

Can Liquid Biopsy Show Whether Cancer Treatment Is Working?

Certain tests may provide information about tumour-related genetic changes over time. However, results should be interpreted alongside symptoms, clinical assessments, imaging and other investigations. Not every liquid biopsy test is validated for monitoring treatment response.

Is Liquid Biopsy Available in India?

Selected hospitals and diagnostic laboratories in India may offer particular liquid biopsy or molecular testing services. Availability depends on the test and clinical indication, so patients should confirm the service directly with the provider.

How Can International Patients Explore Cancer Testing and Treatment in India?

International patients can discuss their medical records and clinical requirements with their treating doctor and explore suitable hospitals and specialists. Contact Welltara to learn about hospital coordination and practical arrangements, subject to service availability and the hospital's assessment.

Medical Disclaimer

This article is intended for general information and educational purposes only. It does not constitute medical advice, diagnosis or treatment recommendations. Liquid biopsy testing should be considered only after discussion with a qualified healthcare professional. Test performance and clinical suitability vary by test and cancer type. Welltara is a healthcare facilitation service and does not diagnose, prescribe or guarantee medical outcomes. Please consult a qualified oncologist for decisions about cancer screening, diagnosis or treatment.

References and Further Reading

Ready to start
your treatment journey?

Share your medical requirement and our care team will assist you with suitable doctors,

treatment options, and next steps.

Get to Free